PROTOCOL
VascuNet™ Pericyte Co-Culture Assay
VascuNet™Pericyte共培養試驗
Vasculogenesis and angiogenesis are the mechanisms responsible for the development of a vascular network. Both endothelial cells and pericytes are key cell types in these processes. While endothelial cells form the lining of the vessels, pericytes are essential to the development of functional vasculature by stabilizing established vessel structures and facilitating local remodeling for network expansion. In addition to conveying structural support, pericytes are also integral in directing endothelial cells via cell-to-cell contact and paracrine signaling. Pericytes have been shown to co-localize with endothelial cells in both normal and abnormal vasculature, and have been implicated in playing a central role in numerous pathologies, including tumorigenesis, neurodegenerative disorders, and diabetic retinopathy.
血管生成和血管生成是血管網絡發育的機制。內皮細胞和周細胞都是這些過程中的關鍵細胞類型。而內皮 細胞是血管的內層,周細胞通過穩定已建立的血管結構和促進網絡e的局部重塑,對功能血管的發展至關重要。 xpansion。除了傳遞結構支持外,周細胞還通過細胞與細胞的接觸和旁分泌信號來引導內皮細胞。周細胞已被證明為共室細胞。 在正常和異常血管系統中,內皮細胞與血管內皮細胞結合,并參與多種病理學中的中心作用,包括腫瘤發生、神經退行性疾病。 糖尿病視網膜病變。
The VascuNet Pericyte Co-Culture Assay combines human embryonic stem cell (ESI-017)-derived pericytes (PC-M cells) with primary human umbilical vein endothelial cells (HUVECs) in a co-culture system designed for a 96-well plate format. These unique PC-M cells display several key properties of pericytes, including expression of CD146, pro-angiogenic function, and effective stabilization of endothelial tube networks. The HUVECs and PC-M cell co- culture system supports vasculogenic tube assembly, resulting in the generation of extensive tube networks that persists at least 4 to 6 days in culture. Vasculogenic tube networks formed with the VascuNet Pericyte Co-Culture Assay persist over 4 times longer in culture than those formed by other assay systems, allowing researchers to study the relevant timing of delivery and long-term efficacy of pro- and anti-angiogenic compounds.
人胚胎干細胞(esi-017)衍生周細胞(pc-M細胞)與原代人臍靜脈內皮細胞(HUVECs)在共培養系統中的結合。 設計的96井板格式。這些*的pc-M細胞顯示了周細胞的幾個關鍵特性,包括CD 146的表達、促血管生成功能以及內皮細胞的有效穩定。 光管網絡。HUVECs和pc-M細胞共培養系統支持血管生成管的組裝,從而產生了在Cultur至少持續4至6天的廣泛的管狀網絡。 e.用VascuNet Pericyte共培養法形成的致血管網絡在培養過程中的持續時間是其他檢測系統的4倍以上,這使得研究人員可以研究該方法。 促血管生成化合物和抗血管生成化合物的時間安排和長期療效。
REQUIRED MATERIALS所需材料
The VascuNet Pericyte Co-Culture Assay kit contains PC-M cells, HUVECs, and all media components for cell expansion and vasculogenic assay. Each kit undergoes extensive quality control to ensure reproducible vasculogenic tube assembly.
Vascune-周細胞共培養檢測試劑盒含有PC-M細胞、HUVECs和所有用于細胞擴增和血管生成測定的培養基成分。每個套件都進行了全面的質量控制,以確保RPR。 可排卵的血管生成管組裝。
Kit Component | Quantity | Storage Condition |
Cells: | ||
PC-M cells (ESI-017-derived pericytes) p19 | 1 vial ≥ 5.0 × 105 cells/vial | Liquid Nitrogen |
HUVECs (secondary donor pool) p5 | 1 vial ≥ 1.0 × 106 cells/vial | Liquid Nitrogen |
VascuNet Growth Medium Components: | ||
VascuNet Basal Medium | 475 mL | 2 to 8°C |
Recombinant Human VEGF | 0.5 mL | -20°C |
Recombinant Human EGF | 0.5 mL | -20°C |
Recombinant Human IGF-1 | 0.5 mL | -20°C |
Recombinant Human FGF basic | 0.5 mL | -20°C |
Ascorbic Acid | 0.5 mL | -20°C |
Heparin Sulfate | 0.5 mL | -20°C |
Hydrocotrisone Hemisuccinate | 0.5 mL | -20°C |
FBS | 25 mL | -20°C |
L-Glutamine | 25 mL | -20°C |
VascuNet Assay Medium Components: | ||
VascuNet Basal Assay Medium | 95 mL | 2 to 8°C |
L-Glutamine | 5 mL | -20°C |
Negative Control: | ||
Suramin Hexasodium Salt | 0.5 mL, 1 mM in H2O | -20°C |
Ensure that kit components are stored at the indicated temperatures upon kit arrival. The VascuNet Pericyte Co- Culture Assay components are stable for a minimum of 3 months from date of receipt when stored as directed.
確保組件在組件到達時以的溫度存儲。VascuNet Pericyte共同培養測試組件從收到時起至少3個月內是穩定的。 按指示存儲。
附加所需試劑和材料
96孔組織培養板
Experimental Timeline
Assay Set-up
實驗時間線
Row 1: Control Row
H: HUVEC Monoculture Reference (40,000 cells/well)
P: PC-M Monoculture Reference (2,000 cells/well)
C: Co-Cultures (20:1 ratio of HUVEC:PC-M; 40,000 HUVECs and 2,000 PC-M cells/well)
Blue: HUVEC & PC-M Cell Co-Culture (Positive Control)
Yellow: HUVEC & PC-M Cell Co-Culture with 50 µM Suramin Hexasodium Salt (Negative Control)
第1行:控制行
h:HUVEC單一培養參考資料(40,000個細胞/井)
P:PC-M單細胞培養參比(2,000個細胞/井)
C:共培養(20:1的HUVEC:PC-M;40,000 HUVECs和2,000個PC-M細胞/井)
藍:HUVEC&PC-M細胞共培養(陽性對照)
黃:HUVEC&PC-M細胞與50 M蘇拉明六鈉鹽共培養(陰性對照
Figure 1. Example assay set-up in a 96-well plate. The first row of the VascuNet Pericyte Co-Culture Assay is a control row, containing triplicate samples of monoculture wells and positive and negative control co-culture wells. The remaining 84 wells of the plate may be used for test compounds. Test compound assays may be performed following the same mono- and co-culture set-up as the control row, or simply as co-culture wells.
圖1.在一個96井的平板上進行測試。VascunetPericyte共培養試驗的行是對照行,包含三份單一培養井的樣本以及陽性和陰性的樣本。 控制共培養井。該板的其余84口井可用作試驗化合物。測試復合測試可以按照與控制行相同的單文化和共培養設置執行。 或者簡單地說是共文化水井。
EXPANSION OF HUVECs AND PC-M CELLS
HUVECs和PC-M細胞的擴增
The HUVECs and PC-M cells must be thawed and expanded individually for two days before they can be plated for the experimental set-up in a co-culture format.
Monitor cell proliferation, and do not allow either the HUVECs or PC-M cells to proliferate to more than 90% confluency during expansion. At high confluency dense cell clusters may form, which can decrease vasculogenic tube assembly in mono- and co-cultures.
HUVECs和PC-M細胞必須單獨解凍和擴張兩天,然后才能以共同培養的形式進行實驗設置。
監測細胞增殖,不允許HUVECs或PC-M細胞在擴張過程中增殖至90%以上。在高匯合度時,可形成密集的細胞團簇。 單培養和共培養時血管生成管的組裝。
Prepare VascuNet Growth Medium for HUVECs and PC-M Cell Expansion
rhVEGF, rhEGF, rhIGF-1, rhFGF basic, Ascorbic Acid, Heparin Sulfate, Hydrocortosone Hemisuccinate, FBS, L-Glutamine
HUVECs和PC-M細胞擴增用VascuNet生長培養基的制備
將以下VascuNet生長介質從-20℃儲存中移除,并允許下列試劑在2至8℃解凍:
rhVEGF,rhEGF,rhIGF-1,rhFGF堿性,抗壞血酸,硫酸肝素,半琥珀酸氫皮質酮,FBS,L-谷氨酰胺
VascuNet Basal Medium 475 mL
rhVEGF 0.5 mL
rhEGF 0.5 mL
rhIGF-1 0.5 mL
rhFGF basic 0.5 mL
Ascorbic Acid 0.5 mL
Heparin Sulfate 0.5 mL Hydrocotrisone Hemisuccinate 0.5 mL FBS 25 mL
通過結合下面列出的所有試劑,準備VascuNet生長培養基。
VascuNet Basal培養基475 mL
rhVEGF 0.5 mL
rhEGF 0.5 mL
rhIGF-1 0.5 mL
rhFGF堿性0.5 mL
抗壞血酸0.5mL
硫酸肝素0.5 mL氫曲松半琥珀酸0.5 mL FBS 25 mL
L-谷氨酰胺25 mL
吸出上清液,在10 mL的VascuNet培養基中輕輕懸浮細胞顆粒。
Thaw and Plate PC-M Cells for Expansion 用于膨脹的解凍板PC-M電池
Note: The PC-M cells are plated at a higher density than the HUVECs.注:PC-M細胞的密度高于HUVECs.
37°C條件下,5%CO2加濕培養細胞
Once the HUVECs and PC-M cells have been expanded, the HUVEC and PC-M cells are plated in co-cultures and monoculture wells of a 96-well plate for the angiogenesis assay. Experimental and control assay wells are established to determine the effects of test compounds on angiogenesis.一旦HUVECs和PC-M細胞被擴增,HUVEC和PC-M細胞被鍍在96孔板的共培養和單培養井中進行血管生成實驗。試驗與控制驢 我們建立了測試井,以確定試驗化合物對血管生成的影響。
Prepare 96-well Assay Plate制備96井試井板
Note: Thaw a sufficient amount of GFR Matrigel to coat the total amount of wells used for the experiment, including the control row (see Fig. 1). Each well used in the assay will require 50 µL of Matrigel solution.注:融化足夠數量的GFR Matrigel,以覆蓋總數量的井用于實驗,包括控制排(見圖1)。在分析中使用的每一口井都需要50升的MAT。 Rigel溶液
Note: The GFR Matrigel will solidify rapidly when warmed above 2 to 8°C. To ensure even coating and distribution of the matrix, keep all of the reagents, tips, and plate on ice.注:GFR Matrigel在溫度高于2°~8°C時會迅速凝固,以保證基體的均勻涂層和分布,使所有試劑、針尖和平板保持在冰上。
VascuNet Basal Assay Medium 95 mL VascuNet Basal試驗培養基95 mL
L-Glutamine 5 mL L-谷氨酰胺5mL
將剩余的VascuNet檢測介質保存在2至8°C處,多2周。
Note: It is essential to thoroughly resuspend the cells to single-cell suspension before plating for the angiogenic assay.注:在進行血管生成試驗前,必須將細胞*重新懸浮到單細胞懸浮液中。
Note: It is essential to thoroughly resuspend the cells to single-cell suspension before plating for the angiogenic assay.注:在進行血管生成試驗前,必須將細胞*重新懸浮到單細胞懸浮液中。
在VascuNet檢測培養基中稀釋PC-M細胞,濃度為1x105個活細胞/mL。
Refer to sample plate set-up diagram (Fig. 1). In addition to the experimental wells, one row of the 96-well plate will be utilized for control wells. Determine the total number of cells needed, in addition to the control row, based on the number of test samples.參考樣板設置圖(圖1).除試驗井外,96口井板中的一行井將用于控制井。確定所需單元格的總數,在 到控制行,根據測試樣本的數量。
Note: This will make a 20:1 ratio of HUVEC:PC-M cells.注:這將使HUVEC:PC-M細胞的比例達到20:1.
Following the 4 to 6 hour incubation period, visualy inspect the wells to confirm attachment and tube formation in both HUVEC monocultures and co-culture conditions (see Fig. 2). After confirmation of initial tube formation,
the cells are ready to be treated with the test reagents. For best results, this is done 4 to 6 hours after plating, but must be completed within 24 hours after cells are plated.在4到6小時的潛伏期后,目視檢查水井,以確定在HUVEC單細胞培養和共培養條件下的附著和管狀形成(見圖2)。確認后 初的管狀,這些細胞已準備好用試驗試劑處理。為了取得良好的效果,這是在電鍍后4至6小時,但必須在24小時內完成電池被鍍。
Figure 2. VascuNet HUVEC and PC-M Cell Co-Culture at 4 hours. Co-Culture of HUVEC and PC-M cells seeded at a 20:1 ratio begin formation of tube networks as early as 4 hours.
圖2.VascuNet HUVEC和PC-M細胞共培養4小時.人臍靜脈內皮細胞(HUVEC)與PC-M細胞按20:1比例共培養,4小時開始形成管狀網絡。
Positive control wells contain cells in co-culture at a 20:1 (HUVEC:PC-M cell) ratio in VascuNet Assay Medium. No additional compounds are added to these wells.陽性對照井在VascuNet檢測培養基中含有20:1(HUVEC:PC-M細胞)比例的細胞。在這些井中不添加任何額外的化合物。
The negative control samples are run in triplicate co-culture conditions with 50 µM Suramin Hexasodium Salt.陰性對照樣品一式三份,共培養條件為50 m蘇拉明六鈉鹽。
Experimental wells should be tested in co-culture wells in triplicates. Triplicate monoculture samples can also be run for comparison.實驗威爾斯應在共培養威爾斯中試驗三次。三份的單一栽培樣品也可用于比較。
Note: Vascular tube formations in co-cultures containing both HUVECs and PC-M cells will be stable for at least 4 days in culture without the need to replace media or add exogenous factors.每4至24小時觀察和成像細胞,以監測血管生成管的組裝和穩定性。
注:在含有HUVECs和PC-M細胞的共培養中,血管管狀細胞在培養中至少穩定4天,不需要更換培養基或添加外源因子。
The following data describes the expected results for co-culture and monoculture conditions at the recommended cell seeding density of 42,000 cells per well containing a 20:1 ratio of HUVECs to PC-M cells (40,000 HUVECs and 2,000 PC-M cells).以下數據描述了在建議的細胞播種密度為每井42,000個細胞時,共培養和單一培養條件下的預期結果,其中含有20:1的HUVECs與pc-m的比例。 細胞(40,000 HUVECs和2,000個PC-M細胞).
Figure 3. Stability of tube structures over time. HUVEC monocultures (rows 1 and 2) seeded at 120,000 cells/cm2 and stained with Vybrant DiO (green), show tube formation on Day 1 post seeding. By day 2, degredation of the vessels is already observed. In contrast, tube structures with multiple branching points are visible from Day 1 and are still stable at Day 6 in the HUVEC and PC-M cell co-cultured wells plated at a 20:1 ratio (rows 3 and 4). PC-M cells are stained red with Vybrant Dil.
Images were taken at 4X magnification.
圖3.隨著時間的推移,管狀結構的穩定性。HUVEC單眼(第1行和第2行)在12萬個細胞/cm2下播種,用VybrantDio(綠色)染色,在播種后第1天出現管狀形成。白天 2、已觀察到船舶的高度。相比之下,具有多個分支點的管狀結構從第1天就可以看到,在HUVEC和pc-M細胞共培養中,在第6天仍保持穩定。 紅色水井按20:1比例鍍制(第3和第4行)。PC-M細胞用Vybrant Dil染紅。
圖像以4X放大倍數拍攝。
APPENDIX
Reagent | Source | Catalog Number |
VascuNet Pericyte Co-Culture Assay | ESI BIO | EM-2202 |
Corning® Matrigel® Growth Factor Reduced (GFR) Basement Membrane Matrix, *LDEV-Free |
Corning |
354230 |
Accutase® Cell Detachment Solution | Innovative Cell Technologies | AT104 – 100 mL |
REFERENCES
Armulik, A., et al. (2005) Endothelial/pericyte interactions. Circ Res 97: 512–523.
Benjamin, L.E., et al. (1998) A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591–1598.
Bergers, G., et al. (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287–1295.
Blocki, A., et al. (2013) Not all MSCs can act as pericytes: functional in vitro assays to distinguish pericytes from other mesenchymal stem cells in angiogenesis. Stem Cells Dev 22: 2347–2355.
Gerhardt, H., and Betsholtz, C. (2003) Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 314: 15–23.
Hamilton, N.B., et al. (2010) Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front Neuroenergetics 2: 5.
Stratman, A.N., et al. (2009) Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood 114: 5091–5101.
von Tell, D., et al. (2006) Pericytes and vascular stability. Exp Cell Res 312: 623–629.
Zimmerlin, L., et al. (2010) Stromal vascular progenitors in adult human adipose tissue. Cytometry A 77A: 22–30.
參考( reference的名詞復數 )
阿穆利克,A,等。(2005)內皮細胞/周細胞相互作用。CIRC RES 97:512—523。
本杰明,L.E.,等人。(1998)血管重塑的可塑性窗口是由預先形成的內皮網絡的周細胞覆蓋來定義的,由PDGF-B和VEGF調節。發展125 : 1591–1598.
Bergers,G.等人.(2003)用激酶抑制劑靶向腫瘤血管中的周細胞和內皮細胞的好處。j克萊因投資111:1287-1295。
Blocki,A.,等人。(2013)并非所有骨髓間充質干細胞都能作為周細胞:體外功能試驗來區分周細胞和其他間充質干細胞在血管生成方面的作用。干細胞研發22:2347-2355。
Gerhardt,H.和Betsholtz,C.(2003)內皮-周細胞在血管生成中的相互作用。細胞組織研究314:15-23。
漢密爾頓,N.B.,等。(2010)圍生體介導的毛細血管直徑調節:健康和疾病中神經的血管耦合的一個組成部分。前神經能量學2:5。
施特拉曼,A.N.,等。(2009)血管生成管組裝過程中圍生細胞的招募刺激內皮基底膜基質的形成。血液114:5091-5101。
馮泰爾,D.(2006)周細胞和血管穩定性。實驗細胞RES 312:623-629。
Zimulin,L,等。(2010)成人脂肪組織間質血管祖細胞。細胞計數A 77:22 - 30。
Matrigel is a registered trademark of Corning, Inc.
Accutase is a trademark of Innovative Cell Technologies, Inc.
© ESI BIO 2015. Unless otherwise noted, ESI BIO, ESI BIO logo and all other trademarks are the property of BioTime, Inc
ESI BIO產品目錄:
貨號 | 品名 | 規格 | 品牌 |
GS310 | HyStem® Hydrogel Kit | 2.5 mL | ESIBIO |
GS311 | HyStem® Hydrogel Kit | 7.5 mL | ESIBIO |
GS1004 | HyStem® Hydrogel Kit | 12.5 mL | ESIBIO |
GS310P | HyStem® Hydrogel Kit w/ PEGSSDA | 2.5 mL | ESIBIO |
GS311P | HyStem® Hydrogel Kit w/ PEGSSDA | 7.5 mL | ESIBIO |
GS312 | HyStem®-C Hydrogel Kit | 2.5 mL | ESIBIO |
GS313 | HyStem®-C Hydrogel Kit | 7.5 mL | ESIBIO |
GS1005 | HyStem®-C Hydrogel Kit | 12.5 mL | ESIBIO |
GS312P | HyStem®-C Hydrogel Kit w/ PEGSSDA | 2.5 mL | ESIBIO |
GS313P | HyStem®-C Hydrogel Kit w/ PEGSSDA | 7.5 mL | ESIBIO |
GS314 | HyStem®-HP Hydrogel Kit | 2.5 mL | ESIBIO |
GS315 | HyStem®-HP Hydrogel Kit | 7.5 mL | ESIBIO |
GS1006 | HyStem®-HP Hydrogel Kit | 12.5 mL | ESIBIO |
GS314P | HyStem®-HP Hydrogel Kit w/ PEGSSDA | 2.5 mL | ESIBIO |
GS315P | HyStem®-HP Hydrogel Kit w/ PEGSSDA | 7.5 mL | ESIBIO |
GS1007 | HyStem® Hydrogel UV QuickSet Kit | 2.5 mL | ESIBIO |
GS1008 | HyStem® Hydrogel UV QuickSet Kit | 7.5 mL | ESIBIO |
GS450 | PEGgel Kit | 1 mL | ESIBIO |
GS240 | DG Water | 10 mL | ESIBIO |
GS241 | DG Water | 20 mL | ESIBIO |
GS3007 | Extralink® Vial | 0.5 mL | ESIBIO |
GS3006 | Extralink® Vial | 2.5 mL | ESIBIO |
GS3009 | Extralink® Lite Vial | 0.5 mL | ESIBIO |
GS3008 | Extralink® Lite Vial | 2.5 mL | ESIBIO |
5050 | Fibronectin | 1 mg | ESIBIO |
GS231 | Gelin-S® Thiol-modified Gelatin | 1 mL | ESIBIO |
GS230 | Gelin-S® Thiol-modified Gelatin | 5 mL | ESIBIO |
GS222 | Glycosil® Hyaluronic Acid | 1 mL | ESIBIO |
GS220 | Glycosil® Hyaluronic Acid | 5 mL | ESIBIO |
GS217 | Heprasil® Hyaluronic Acid | 1 mL | ESIBIO |
GS215 | Heprasil® Hyaluronic Acid | 5 mL | ESIBIO |
5010-D | Nutragen® Bovine Collagen | 50 mL | ESIBIO |
GS711 | PEGDA | 1 mL | ESIBIO |
GS700 | PEGDA | 1 g | ESIBIO |
GS705 | PEGDA | 5 g | ESIBIO |
GS755 | PEGSSDA | 0.5 mL | ESIBIO |
5020 | PEPTITE-2000® RGD Peptide | 5 mg | ESIBIO |
5005-B | PureCol® Collagen | 100 mL | ESIBIO |
5007-A | VitroCol® Collagen | 20 mL | ESIBIO |
5051 | Vitronectin | 0.1 mg | ESIBIO |
EM2203 | ExoSense™ CD63 Exosome ELISA Kit | 96 assays | ESIBIO |
EM2202 | VascuNet™ CoCulture Assay Kit | 1 Kit | ESIBIO |
ST11006 | BioLiteTM SSEA-1 (DyLight 488) anti-Human/Mouse Antibody | 100 µL | ESIBIO |
ST11008 | BioLiteTM TRA-1-81 (DyLight 488) anti-Human Antibody | 100 µL | ESIBIO |
ST11023 | Nestin anti-Human Antibody | 100 µL | ESIBIO |
ST11003 | Oct4 anti-Human/Mouse Antibody | 100 µL | ESIBIO |
ST11001 | Sox2 anti-Human/Mouse Antibody | 100 µL | ESIBIO |
ST11013 | SSEA-1 anti-Human/Mouse Antibody | 100 µL | ESIBIO |
ST11014 | SSEA-3 anti-Human/Mouse Antibody | 100 µL | ESIBIO |
ST11015 | SSEA-4 anti-Human Antibody | 100 µL | ESIBIO |
ST11018 | TRA-1-60 (PE) anti-Human Antibody | 100 µL | ESIBIO |
ST11016 | TRA-1-60 anti-Human Antibody | 100 µL | ESIBIO |
ST11017 | TRA-1-81 anti-Human Antibody | 100 µL | ESIBIO |
ST12007 | LIF, Mouse Recombinant | 10 µg | ESIBIO |
ST12008 | LIF, Mouse Recombinant | 100 µg | ESIBIO |
ES-84 | PureStem® 4D20.8, NCr-fac Progenitor | ea | ESIBIO |
ES-98 | PureStem® E15, Meso-prx/latp Progenitor | ea | ESIBIO |
ES-283 | PureStem® 7PEND24, NCr-fac Progenitor | ea | ESIBIO |
ES-278 | PureStem® 7SMOO32, NCr-fac Progenitor | ea | ESIBIO |
ES-250 | PureStem® SK11, NCr-fac Progenitor | ea | ESIBIO |
ES-268 | PureStem® MEL2, NCr-fac Progenitor | ea | ESIBIO |
ES-256 | PureStem® SM30, NCr-fac Progenitor | ea | ESIBIO |
ES-335 | PureStem® ES-335 Meso-latp Progenitor | ea | ESIBIO |
ES-100 | PureStem® E72 BETATROPHIN+ Progenitor | ea | ESIBIO |
ES-1001 | PureStem® ES-1001 GDF11+ Progenitor | ea | ESIBIO |
ES-184 | PureStem® EN7 Progenitor | ea | ESIBIO |
ES-101 | PureStem® ES-101 Progenitor | ea | ESIBIO |
ES-139 | PureStem® ES-139 Progenitor | ea | ESIBIO |
ES-154 | PureStem® ES-154 Progenitor | ea | ESIBIO |
ES-198 | PureStem® ES-198 Progenitor | ea | ESIBIO |
ES-199 | PureStem® ES-199 Progenitor | ea | ESIBIO |
ES-209 | PureStem® ES-209, Meso-prx/latp Progenitor | ea | ESIBIO |
ES-210 | PureStem® ES-210, Ecto-ntu Progenitor | ea | ESIBIO |
ES-236 | PureStem® ES-236 Progenitor | ea | ESIBIO |
ES-170 | PureStem® E44 Progenitor | ea | ESIBIO |
ES-196 | PureStem® W10 Progenitor | ea | ESIBIO |
ES-194 | PureStem® Z11, Meso Progenitor | ea | ESIBIO |
EM-1001 | PureStem® Progenitor Growth Media, EPM k01 | 500 mL | ESIBIO |
EM-1002 | PureStem® Progenitor Growth Media, EPM k02 | 500 mL | ESIBIO |
EM-1003 | PureStem® Progenitor Growth Media, EPM k03 | 500 mL | ESIBIO |
EM-1004 | PureStem® Progenitor Growth Media, EPM k04 | 500 mL | ESIBIO |
EM-1005 | PureStem® Progenitor Growth Media, EPM k05 | 500 mL | ESIBIO |
EM-1006 | PureStem® Progenitor Growth Media, EPM k06 | 500 mL | ESIBIO |
EM-1007 | PureStem® Progenitor Growth Media, EPM k07 | 500 mL | ESIBIO |
EM-1008 | PureStem® Progenitor Growth Media, EPM k08 | 500 mL | ESIBIO |
EM-2002 | HyStem®-4D Chondrogenesis Differentiation Kit | 1 Kit | ESIBIO |
EM-2007 | HyStem®-4D Differentiation Kit | 1 Kit | ESIBIO |
EM-2001 | PureStem® Chondrogenesis Differentiation Kit | 1 Kit | ESIBIO |
EM-2006 | PureStem® Choroid Plexus Differentiation Kit | 1 Kit | ESIBIO |
EM-2003 | PureStem® Osteogenesis Differentiation Kit 01 | 1 Kit | ESIBIO |
EM-2004 | PureStem® Osteogenesis Differentiation Kit 02 | 1 Kit | ESIBIO |
ST10035 | LY411575 | 5 mg | ESIBIO |
ST10008 | PD0325901 | 2 mg | ESIBIO |
ST10009 | PD0325901 | 10 mg | ESIBIO |
ST10010 | PD0325901 | 415 µL, 10 mM | ESIBIO |
ST10034 | PD173074 | 2 mg | ESIBIO |
ST10021 | RepSox | 5 mg | ESIBIO |
ST10027 | RG108 | 5 mg | ESIBIO |
ST10024 | SB203580 | 2 mg | ESIBIO |
ST10012 | SB431542 | 5 mg | ESIBIO |
ST10013 | SB431542 | 10 mg | ESIBIO |
ST10014 | SB431542 | 1.3 mL, 10 mM | ESIBIO |
ST10025 | SP600125 | 5 mg | ESIBIO |
ST10015 | Thiazovivin | 2 mg | ESIBIO |
ST10017 | XAV939 | 2 mg | ESIBIO |
ST10018 | Y27632 | 2 mg | ESIBIO |
ST10019 | Y27632 | 10 mg | ESIBIO |
ST10020 | Y27632 | 625 µL, 10 mM | ESIBIO |
上海起發實驗試劑有限公司是實驗試劑一站式采購服務商
1:強大的進口輻射能力,血清、抗體、耗材、大部分限制進口品等。
2:產品種類齊全,經營超過700多品牌,基本涵蓋所有生物實驗試劑耗材。
3:提供加急服務,貨品一般1-2周到貨。
4:富有競爭力的價格優勢,絕大部分價格有優勢。
5:多年積累良好的信譽,大部分客戶提供貨到付款服務。客戶包括清華、北大、交大、復旦、中山等100多所高校,ROCHE,阿斯利康、國藥、fisher等知藥企。
6:我們還是Santa,Advanced Biotechnologies Inc,Athens Research & Technology,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. FormuMax Scientific,Inc, Genebridege, Glycotope Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,omicronbio, Polysciences,prospecbi, QA-BIO,quickzyme,RESEARCH DIETS,INC,sterlitech;sysy,TriLink BioTechnologies,Inc;worthington-biochem,zyagen等幾十家國外公司授權代理。
7:我們還是invitrogen,qiagen,MiraiBioam,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等知*批發,歡迎合作。